Insulin is essential for the survival of people with type 1 diabetes and for better management of people with type 2 diabetes. People with diabetes using insulin also require self-monitoring blood glucose (SMBG) devices (e.g., meters, strips, continuous monitoring systems) for day-to-day management. It is essential to ensure that insulin and these devices are available and affordable. This study aimed to evaluate the availability, price, and affordability of insulin and SMBG devices in Indonesia using an adaptation of the World Health Organization/Health Action International (WHO/HAI) price survey. A total of 34 public health facilities (hospitals, primary healthcare centres/Puskesmas) and 37 private pharmacies were sampled. Information from three major online marketplaces was also collected. Prices were expressed as median patient prices (US$). Affordability was defined as the number of days’ wages needed by the lowest paid unskilled government worker (LPGW) to purchase 30 days’ supply of insulin, delivery devices and SMBGs. Availability of analogue insulin was slightly higher in public facilities (63.6%) than in the private sector (43.2%), with no human insulin available in both sectors. Conversely, better availability was observed in private facilities for SMBG devices as public sector facilities did not supply devices for self-testing. Median prices for 1000IU analogues varied between the public sector (US$ 5.26) and the private sector (US$11.24). The highest median price of analogues was seen in online marketplaces (US$ 28.65). The least costly median price of SMBG devices were observed in online platforms (meter: US$ 18.37, test strip: US$ 0.27, lancet: US$ 0.02). A low-income person had to work 2–3 days to buy 1000IU of analogues. It required 5–7 days’ and 4–5 day’s wages to purchase a meter and a month’s supply of test strips, respectively. The availability and affordability of insulin and SMBG devices remain important issues in Indonesia requiring holistic approaches for further improvement.
7 October 2020 in International Journal of Research in Pharmaceutical Sciences
Pneumonia is the leading cause of morbidity and mortality in children worldwide. Antibiotics are the mainstay treatment for bacterial pneumonia so their use should be clearly mentioned in the pneumonia clinical pathway (CP). This study aimed to evaluate the effectiveness of pneumonia CP in pediatrics. A cross-sectional observational study was conducted in a private hospital in Indonesia. The inclusion criteria were pediatric patients admitted with pneumonia in the period of January-December 2017 (pre-CP period) and January-December 2018 (post-CP) and receiving antibiotics. The effectiveness of CP was evaluated according to four parameters: length of stay, clinical outcomes, quality (Gyssens antibiogram) and quantity of antibiotics. A total of 121 eligible patients’ medical records were analyzed (60 before and 61 after CP implementation). Second and third generation cephalosporins (42.1%) predominated the use of antibiotics pre-CP period, whilst aminoglycosides (59.6%) constituted more than half of antibiotic use in post-CP group. More than half of the patients stayed in the hospital not more than 3 days pre-CP period vs 31.1% post-CP period. Nearly all patients had good clinical outcomes during hospitalization between both periods. The proportion of quality of antibiotics was less than 5% either before or after CP implementation. The quantity of antibiotics post-CP (408.42 defined daily dose/DDD per 100 patient days) was almost two times of pre-CP period (222.42 DDD per 100 patient days). In conclusion, implementation of CP could not achieve the targeted goals to reduce the length of hospitalization and improve the antibiotic use. No discernible difference was observed in clinical outcomes before and after CP implementation.
Several pharmaceutical companies have long complained that the price of medicines that win the e-catalogue tender is too low, in some cases even below the cost of production. However, it should not be a concern that only pharmaceutical products with regulation of Indonesian food and drug (BPOM) distribution licenses are eligible for the price tender, as they are of good quality. This study aims to determine the quality and potency of three antibiotic drugs based on their highest utilization (DU 90%) in pneumonia patients at two hospitals, A (ceftriaxone, azithromycin tablet) and B (ceftriaxone, levofloxacin infusion) compared to brand name. The quality of the samples was evaluated following the Indonesian Pharmacopoeia 6th Edition (FI-VI). Antibiotic potency was assessed using the Plate-Cylinder Method with K. pneumonia from human and S. pneumonia ATCC 10015 as the test bacteria evaluated following CLSI. All samples meet the criteria of FI-VI antibiotic content, weight uniformity, dissolution. Antibiotic potency all samples test S.pneumonia and K.pneumonia were sensitive but ceftriaxone test with K.pneumonia was resistance. All antibiotic tablets and injections studied met the requirements of the Indonesian Pharmacopoeia Edition 6 for active medicinal ingredient content, dosage weight uniformity, and dissolution. All drugs from hospitals (INN) have lower antibiotic potency than branded drugs. This highlight the importance of conducting microbiological testing on antibiotic preparations.
2 July 2025 in Journal of Pharmaceutical Policy and Practice
In 2015, Indonesia Ministry of Health (MoH) issued a decree to ensure the affordability of medicines by providing transparent prices which obliged all manufacturers to print a maximum retail price (MRP) on medicine primary packaging. We measure the compliance of manufacturers and retailers with the regulation stated in the decree and estimate the retailers’ profit. Five essential medicines (allopurinol, amlodipine, amoxicillin, cefixime, dexamethasone) were purchased from randomly selected health facilities, retail pharmacies and online outlets in Indonesia. We recorded retailer’s selling price and product’s MRP. We also sourced product’s list price and sales volume from pharmaceutical market data. We conducted an MRP policy implementation analysis by evaluating three indicators (retail price transparency, permitted MRP and permitted sales price). We also estimated the retailers’ profit by taking into account the profit margin and sales volume. Of 1249 sampled medicines, nearly all samples (99.4%) had visible MRP on their packaging indicating high transparency compliance. For unbranded generics, none complied with permitted MRP with a median ratio of printed MRP to permitted MRP being 3.5 (IQR 2.6–7.9), whilst higher compliance (11.2%) was observed for branded generics (IQR 1.1–1.7, median 1.1). 33% of the samples were sold above the printed MRP with the lowest compliance to actual selling price being documented in hospitals. Branded generics accounted for 79% of the product value across the study medicines and generated more profits than the unbranded versions. The transparency implementation through printed MRP and the compliance with permitted sales price regulation contribute to retailer accountability. Rules restricting permitted MRPs for unbranded generics, irrational since their inception, while they never set any limits at all on the price of branded medicines. This showed not enough evidence that the policy contributed to its objective of ensuring affordability.
BACKGROUND People buy medicines online for various reasons, such as convenience and cost savings. In Indonesia, the Ministry of Health allows registered platforms to sell medicines online; however, unregistered sellers are still widely circulated. While numerous studies have highlighted the quality of online medicines, comparisons with medicines purchased from licensed physical pharmacies are rare. OBJECTIVE To explore the conveniences of buying medicine online on several online platforms in Indonesia, investigate the quality, and compare the price and quality of medicine bought online to medicine purchased in physical pharmacies. METHODS The online sellers were categorised by regulatory status, and the conveniences of each were explored. Between February and May 2022, samples were collected from 732 physical pharmacies and 328 online platforms. Quality and price comparisons were conducted across different types of medicine sellers. RESULTS Obtaining samples from other online sellers was not always easy. Some platforms have complex registration processes, and we found locating unregulated sellers challenging. Notably, 58.8% of sampled medicines exceeded the median retail price from physical pharmacies for the same dose and form. Branded generic medicines exhibited the widest price variation, ranging from 0.15 to 16.4 times the median offline retail price, while generic medicines ranged from 0.18 to 4.1 times. Regarding quality, the failure rates were 7.9% online and 8.7% offline, showing no significant difference. Among online sellers, unregulated ones had a higher failure rate (11.2%) compared to regulated (3.0%) and semi-regulated (4.5%) sellers. Antibiotics were 2.6 times more likely to fail quality tests than other medicines (13.8% vs. 5.1%). CONCLUSIONS The conveniences of purchasing medicine online vary among sellers, and prices are not consistently lower than offline sellers. In terms of quality, as long as patients buy medicine online from regulated sellers, they don’t have to worry about the quality of medicines.
30 October 2022 in JURNAL ILMU KEFARMASIAN INDONESIA
The provision of single-dose prophylactic antibiotics within 30 to 60 minutes before caesarean has been highly recommended, yet its implementation in hospitals varies considerably. This research aimed to analyze the cost-effectiveness of prophylactic antibiotics given a single dose versus multiple doses during caesarean section surgery. A retrospective observational study with a crosssectional design involved pregnant women undergoing caesarean section and receiving a ceftriaxone single dose before surgery (Group 1) versus those receiving multiple ceftriaxone doses (Group 2). The study calculated direct medical costs (hospital perspective), with surgical site infection (SSI) as the effectiveness parameter. The chi-square test was used to compare SSI between the two groups. There were 806 patients (group 1) and A total of 250 patients (Group 2) met the inclusion criteria. Analysis of total cost revealed no significant difference between both groups (approximately IDR 13,000,000/patient), yet patients receiving prolonged Ceftriaxone were associated with significantly higher antibiotic costs (p-0.000). The study documented 1.2% SSI in Group 1 and 0.8% in Group 2 (p=0.742). Calculation of the incremental cost-effectiveness ratio found that an extra IDR 3,278,000 was needed to provide additional success to prevent SSI by administering multiple doses of ceftriaxone. In conclusion, a single dose prophylactic antibiotic provides comparable efficacy to a multiple-dose regimen, but at a lower cost.